Loading
Laekna is a Shanghai drug company listed in Hong Kong. Its lead cancer medicine, afuresertib, taken with fulvestrant for a common type of advanced breast cancer, met its main goal in a phase 3 trial and has been submitted for approval in China. It also works on obesity and liver fibrosis.
Laekna Therapeutics was established in 2016 in Shanghai and listed on the Main Board of the Hong Kong Stock Exchange in June 2023 (stock code 2105). It works in metabolic disease, oncology and liver fibrosis. Its lead oncology asset is afuresertib (LAE002), an AKT inhibitor licensed from Novartis in 2018: the company says the phase 3 AFFIRM-205 trial of afuresertib plus fulvestrant in HR-positive, HER2-negative locally advanced or metastatic breast cancer (NCT04851613) met its primary endpoint, a new drug application was accepted by China's NMPA in August 2026, and China rights for breast cancer were licensed to Qilu Pharma in November 2025. Afuresertib has also been studied with lapiteronel (LAE001, a CYP17A/CYP11B2 inhibitor licensed from Novartis) in metastatic castration-resistant prostate cancer, with LAE005 (anti-PD-L1) and nab-paclitaxel in triple-negative breast cancer, and with paclitaxel in platinum-resistant ovarian cancer. LAE118, a PI3K-alpha mutant-selective inhibitor, entered phase 1 in advanced solid tumours in 2026 and was licensed outside China to Vasque Bio. Preclinical cancer programmes listed include LAE120 (USP1), LAE119 (PARP1), LAE111 (LILRB1/LILRB2), LAE112 (FGFR2b) and LAE113 (TIGIT/PVRIG).
Afuresertib is an experimental pill from Laekna Therapeutics, in phase 3 trials for HR-positive, HER2-negative breast cancer.
Lapiteronel is an experimental pill from Laekna Therapeutics, in phase 2 trials for metastatic castration-resistant prostate cancer.
LAE118 is an experimental pill from Laekna Therapeutics, in phase 1 trials for advanced solid tumours.
Shares OrbiMed, AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha.
Shares OrbiMed, AKT, PI3K, AKT and mTOR inhibitors.
Shares AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Shares AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, Triple-negative breast cancer (TNBC).
Shares AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, Triple-negative breast cancer (TNBC).
Shares AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, Triple-negative breast cancer (TNBC).
Shares AKT, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Shares PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/